Statement of Changes in Beneficial Ownership (4)
November 05 2020 - 04:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person * IVERS-READ GILLIAN
C |
2. Issuer Name and Ticker or Trading
Symbol Clovis Oncology, Inc. [ CLVS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
See Remarks |
|
(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE
100 |
3. Date of Earliest Transaction (MM/DD/YYYY)
11/3/2020
|
|
(Street)
BOULDER, CO 80301
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
|
Common Stock |
11/3/2020 |
|
M |
|
3749 |
A |
(1) |
216480 |
D |
|
|
Common Stock |
11/3/2020 |
|
S |
|
1689 (2) |
D |
$4.93 |
214791 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Restricted Stock Units |
(1) |
11/3/2020 (3) |
|
M |
|
|
3749 |
(3) |
(3) |
Common Stock |
3749 |
$0.00 |
33744 |
D |
|
| Explanation of
Responses: |
| (1) |
Each Restricted Stock Unit
represents the right to receive one share of Common
Stock. |
| (2) |
Represents the shares
automatically sold by the reporting person pursuant to an election
to satisfy tax withholding obligations in connection with the
vesting of the Restricted Stock Units listed in Table II. This sale
does not represent a discretionary trade by the reporting
person. |
| (3) |
On February 1, 2019, the
reporting person was granted 59,988 Restricted Stock Units. 25% of
such Restricted Stock Units vested on February 1, 2020, and the
remainder vests in substantially equal installments over the 12
quarters immediately following such date. |
Remarks:
Executive Vice President of Technical Operations and Chief
Regulatory Officer |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
IVERS-READ GILLIAN C
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER, CO 80301 |
|
|
See Remarks |
|
Signatures
|
|
/s/ Gillian Ivers-Read |
|
11/5/2020 |
| **Signature of Reporting
Person |
Date |
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Dec 2020 to Jan 2021
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Jan 2020 to Jan 2021
